These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
334 related articles for article (PubMed ID: 10597783)
41. The efficacy of combined zidovudine and lamivudine compared with that of combined zidovudine, lamivudine and nelfinavir in asymptomatic and early symptomatic HIV-infected children. Moolasart P; Likanonsakul S Southeast Asian J Trop Med Public Health; 2002 Jun; 33(2):280-7. PubMed ID: 12236426 [TBL] [Abstract][Full Text] [Related]
42. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group. Katlama C; Ingrand D; Loveday C; Clumeck N; Mallolas J; Staszewski S; Johnson M; Hill AM; Pearce G; McDade H JAMA; 1996 Jul; 276(2):118-25. PubMed ID: 8656503 [TBL] [Abstract][Full Text] [Related]
43. The treatment of antiretroviral-naive subjects with the 3TC/zidovudine combination: a review of North American (NUCA 3001) and European (NUCB 3001) trials. Eron JJ AIDS; 1996 Dec; 10 Suppl 5():S11-9. PubMed ID: 9030391 [TBL] [Abstract][Full Text] [Related]
44. Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study. Wolbers M; Opravil M; von Wyl V; Hirschel B; Furrer H; Cavassini M; Vernazza P; Bernasconi E; Battegay M; Yerly S; Günthard H; Bucher HC; AIDS; 2007 Oct; 21(16):2201-7. PubMed ID: 18090047 [TBL] [Abstract][Full Text] [Related]
45. A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study. Carr A; Chuah J; Hudson J; French M; Hoy J; Law M; Sayer D; Emery S; Cooper DA AIDS; 2000 Jun; 14(9):1171-80. PubMed ID: 10894281 [TBL] [Abstract][Full Text] [Related]
46. Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study. Gathe JC; Wood R; Sanne I; DeJesus E; Schürmann D; Gladysz A; Garris C; Givens N; Elston R; Yeo J Clin Ther; 2006 May; 28(5):745-54. PubMed ID: 16861096 [TBL] [Abstract][Full Text] [Related]
47. Effect of antiretroviral combination therapy (zidovudine/didanosine or zidovudine/lamivudine) on quantitative plasma human immunodeficiency virus-ribonucleic acid in children and adolescents infected with human immunodeficiency virus. Sölder B; Wintergerst U; Notheis G; Eberle J; Gürtler L; Belohradsky BH J Pediatr; 1997 Feb; 130(2):293-9. PubMed ID: 9042135 [TBL] [Abstract][Full Text] [Related]
48. Decrease of HIV-1 RNA levels in lymphoid tissue and peripheral blood during treatment with ritonavir, lamivudine and zidovudine. Ritonavir/3TC/ZDV Study Group. Notermans DW; Jurriaans S; de Wolf F; Foudraine NA; de Jong JJ; Cavert W; Schuwirth CM; Kauffmann RH; Meenhorst PL; McDade H; Goodwin C; Leonard JM; Goudsmit J; Danner SA AIDS; 1998 Jan; 12(2):167-73. PubMed ID: 9468365 [TBL] [Abstract][Full Text] [Related]
49. Concentration-controlled compared with conventional antiretroviral therapy for HIV infection. Fletcher CV; Anderson PL; Kakuda TN; Schacker TW; Henry K; Gross CR; Brundage RC AIDS; 2002 Mar; 16(4):551-60. PubMed ID: 11872998 [TBL] [Abstract][Full Text] [Related]
50. Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice. Lackey P; Mills A; Carpio F; Hsu R; DeJesus E; Pierone G; Henegar C; Fusco J; Fusco G; Wohlfeiler M Clin Drug Investig; 2017 Jan; 37(1):51-60. PubMed ID: 27587070 [TBL] [Abstract][Full Text] [Related]
51. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006. Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758 [TBL] [Abstract][Full Text] [Related]
52. Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children: a randomized controlled trial. Pediatric AIDS Clinical Trials Group 338 Study Team. Nachman SA; Stanley K; Yogev R; Pelton S; Wiznia A; Lee S; Mofenson L; Fiscus S; Rathore M; Jimenez E; Borkowsky W; Pitt J; Smith ME; Wells B; McIntosh K JAMA; 2000 Jan; 283(4):492-8. PubMed ID: 10659875 [TBL] [Abstract][Full Text] [Related]
53. Contribution of different antiretroviral regimens containing zidovudine, lamivudine and ritonavir-boosted lopinavir on HIV viral load reduction during pregnancy. Sripan P; Le Coeur S; Ingsrisawang L; Cressey TR; Bouazza N; Foissac F; Ngo-Giang-Huong N; Traisathit P; Srirompotong U; Ayudhaya OP; Puangsombat A; Jungpipun J; Jittayanun K; Tréluyer JM; Jourdain G; Lallemant M; Urien S Antivir Ther; 2016; 21(5):435-40. PubMed ID: 26492107 [TBL] [Abstract][Full Text] [Related]
54. Early versus delayed fixed dose combination abacavir/lamivudine/zidovudine in patients with HIV and tuberculosis in Tanzania. Shao HJ; Crump JA; Ramadhani HO; Uiso LO; Ole-Nguyaine S; Moon AM; Kiwera RA; Woods CW; Shao JF; Bartlett JA; Thielman NM AIDS Res Hum Retroviruses; 2009 Dec; 25(12):1277-85. PubMed ID: 20001518 [TBL] [Abstract][Full Text] [Related]
55. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes. Mootsikapun P; Chetchotisakd P; Anunnatsiri S; Boonyaprawit P Antivir Ther; 2005; 10(8):911-6. PubMed ID: 16430196 [TBL] [Abstract][Full Text] [Related]